Vera Therapeutics, Inc.

NASDAQ:VERA

37.51 (USD) • At close September 13, 2024
Bedrijfsnaam Vera Therapeutics, Inc.
Symbool VERA
Munteenheid USD
Prijs 37.51
Beurswaarde 2,056,587,027
Dividendpercentage 0%
52-weken bereik 9.24 - 50.78
Industrie Biotechnology
Sector Healthcare
CEO Dr. Marshall Fordyce M.D.
Website https://veratx.com

An error occurred while fetching data.

Over Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A

Vergelijkbare Aandelen

908 Devices Inc. logo

908 Devices Inc.

MASS

3.6 USD

Bionano Genomics, Inc. logo

Bionano Genomics, Inc.

BNGO

0.43 USD

CareMax, Inc. logo

CareMax, Inc.

CMAX

2.04 USD

Cara Therapeutics, Inc. logo

Cara Therapeutics, Inc.

CARA

0.263 USD

Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc.

ARCT

20.75 USD

Alpha Tau Medical Ltd. logo

Alpha Tau Medical Ltd.

DRTS

2.34 USD

Day One Biopharmaceuticals, Inc. logo

Day One Biopharmaceuticals, Inc.

DAWN

14.13 USD

2seventy bio, Inc. logo

2seventy bio, Inc.

TSVT

4.71 USD

Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc.

NAUT

2.9 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)